CN106727476A - A kind of composition and its application in animal muscle fiber types is improved - Google Patents
A kind of composition and its application in animal muscle fiber types is improved Download PDFInfo
- Publication number
- CN106727476A CN106727476A CN201611131091.8A CN201611131091A CN106727476A CN 106727476 A CN106727476 A CN 106727476A CN 201611131091 A CN201611131091 A CN 201611131091A CN 106727476 A CN106727476 A CN 106727476A
- Authority
- CN
- China
- Prior art keywords
- composition
- application
- content
- product
- butanedioic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
Abstract
The invention belongs to athletic physiology research field, more particularly to a kind of composition and its application in animal muscle fiber types is improved.The invention provides a kind of composition, including:One or more in butanedioic acid, succinic acid derivative and butanedioic acid metabolite.Present invention also offers application of the above-mentioned composition in the quality for improving exercise tolerance, improving content of hemoglobin, improve myoglobin content, reduce blood-sugar content, reduction blood fat content, promote Wound healing and improvement meat.Through experimental tests can be obtained, the composition that the present invention is provided, and effectively can quickly change humans and animals muscle fiber types.Meanwhile, in the composition that the present invention is provided, the succinate that butanedioic acid is formed in vivo belongs to the conventional intermediate product of internal metabolism, and the generation of adverse reaction will not be typically caused to human body.Solve in the prior art, the quick method for changing humans and animals muscle fiber types has the technological deficiency that adverse reaction is more, range of application is narrow and is difficult to realization.
Description
Technical field
The invention belongs to athletic physiology research field, more particularly to a kind of composition and its improving animal muscle fibre class
Application in type.
Background technology
The type of animal muscle is generally divided into fast muscle and slow muscle two types, myoglobulin heavy chain knot contained by fast muscle and slow muscle
There is notable difference in structure and metabolic way;Wherein, based on IIb fiber types, its energy source relies primarily on glycolysis to fast muscle,
Rich in a large amount of glycogens;And slow muscle is based on I fiber types, its energy source can be the aerobic oxygen of carbohydrate and aliphatic acid
Change, the organelle-mitochondria of intracellular myoglobins and aerobic oxidation rich in storage oxygen.
The type of muscle is the key of the locomitivity of the energetic supersession and animal/people that determine body.Animal body slow muscle
The raising of ratio can increase the aerobic oxidation of sugar and aliphatic acid, thus effectively reduce blood sugar and blood lipid level.Meanwhile, it is rich in slow muscle
Containing mitochondria and myoglobins, the energy and oxygen of abundance can be provided for motion for a long time, so as to greatly improve fortune
Kinetic force.And slow muscle metabolism produces little lactic acid, can greatly improve the anti-fatigue ability of animal/people.
The type of muscle also determines the meat quality of animal, and the meat of animal is including yellowish pink, drip loss etc..Generally,
Captive animal motion is few, and muscle types are based on white muscle.Zai Hou animal muscle tissues fast glycolytic simultaneously produces a large amount of lactic acid, mistake
The lactic acid of amount causes muscle protein to be separated out near isoelectric point and combines water, and this is to cause muscle appearance pale and infiltration main
Reason.In contrast, the muscle based on slow muscle is then yellowish pink ruddy, and drip loss is greatly reduced, and also extends the shelf life of meat.
In the prior art, the quick method for changing humans and animals muscle fiber types is mainly increase motion or injection illicit drug
Thing, although injection hematopoietin etc. can increase hemoglobin and myoglobins, improves locomitivity, and the method is not
Only obvious adverse reaction, and forbidden by most Physical Culture and Sports Associations.If sportsman wrongly takes forbidden drug or eats injection by mistake
The meat of fruit forbidden drug, once being monitored by linked groups, can produce serious adverse effect to its sports career.To have
The muscle fiber types that effect changes humans and animals generally needs more than 6 weeks, and daily 1h's jogs or do low for a long time in high altitude localities
Oxygen acclimatization is moved, and is had the shortcomings that action is slow, is difficult to.In sum, in the prior art, it is quick to change humans and animals flesh fibre
Tieing up the method for type has the technological deficiency that adverse reaction is more, range of application is narrow and is difficult to realization.
Therefore, a kind of composition and its application in animal muscle fiber types is improved are developed, for solving existing skill
In art, the quick method for changing humans and animals muscle fiber types has that adverse reaction is more, range of application is narrow and is difficult to realization
Technological deficiency, becomes those skilled in the art's problem demanding prompt solution.
The content of the invention
In view of this, the invention provides a kind of composition and its application in animal muscle fiber types is improved, it is used for
Solve in the prior art, the quick method for changing humans and animals muscle fiber types have that adverse reaction is more, range of application is narrow and
It is difficult to the technological deficiency realized.
The invention provides a kind of composition, the composition includes:Butanedioic acid, succinic acid derivative and amber acid metabolic
One or more in product.
Preferably, in terms of mass parts, the composition includes:0~100 part of butanedioic acid, 0~100 part of succinic acid derivative
With 0~100 part of butanedioic acid metabolite.
Preferably, the succinic acid derivative is selected from:Succinate, methyl succinate, ethyl succinate, butanedioic acid third
One or more in ester, and amber acid glyceride.
Preferably, the butanedioic acid metabolite is selected from:In fumaric acid, hydroxy succinic acid and methylsuccinic acid one
Plant or various.
The present invention also provides a kind of application of composition including described in any of the above one in exercise tolerance is improved.
The present invention also provide a kind of composition including described in any of the above one in content of hemoglobin is improved should
With.
The present invention also provide a kind of composition including described in any of the above one in myoglobin content is improved should
With.
The present invention also provides a kind of application of composition including described in any of the above one in blood-sugar content is reduced.
The present invention also provides a kind of application of composition including described in any of the above one in reduction blood fat content.
The present invention also provides a kind of application of composition including described in any of the above one in wound healing.
The present invention also provides a kind of application of composition including described in any of the above one in the quality of improvement meat.
In sum, the invention provides a kind of composition, the composition includes:Butanedioic acid, succinic acid derivative and
One or more in butanedioic acid metabolite.Improving exercise tolerance, improving blood red present invention also offers above-mentioned composition
Answering in the quality of protein content, raising myoglobin content, reduction blood-sugar content, reduction blood fat content and improvement meat
With.Through experimental tests can be obtained, the composition that the present invention is provided, and can be effectively improved exercise tolerance, be improved content of hemoglobin, improve
Myoglobin content, reduce blood-sugar content, reduction blood fat content and improvement meat quality, effectively can quickly change people and
Animal muscle fiber types.Meanwhile, in the composition that the present invention is provided, the succinate that butanedioic acid is gone in vivo belongs to internal generation
The conventional intermediate product thanked, the generation of adverse reaction will not be typically caused to human body.Solve in the prior art, quickly change people
There is the technological deficiency that adverse reaction is more, range of application is narrow and is difficult to realization with the method for animal muscle fiber types.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
The accompanying drawing to be used needed for having technology description is briefly described, it should be apparent that, drawings in the following description are only this
Inventive embodiment, for those of ordinary skill in the art, on the premise of not paying creative work, can also basis
The accompanying drawing of offer obtains other accompanying drawings.
During Fig. 1 is for the specific embodiment of description of the invention, in embodiment 2, mouse running endurance after product 7 is taken
As a result;
In the specific embodiment of Fig. 2 description of the invention, in embodiment 2, the knot of mouse maximum grip after product 7 is taken
Really;
In the specific embodiment of Fig. 3 description of the invention, in embodiment 3, mouse content of hemoglobin after product 7 is taken
Result;
In the specific embodiment of Fig. 4 description of the invention, in embodiment 4, flesh red eggs in mouse muscle are taken after product 7
The result of Bai Hanliang;
In the specific embodiment of Fig. 5 description of the invention, in embodiment 5, mouse blood sugar index knot after product 7 is taken
Really;
In the specific embodiment of Fig. 6 description of the invention, in embodiment 6, mice serum free-fat after product 7 is taken
Sour index result;
In the specific embodiment of Fig. 7 description of the invention, in embodiment 7, mouse wound healing time after product 7 is taken
Result.
Specific embodiment
The invention provides a kind of composition and its application in animal muscle fiber types is improved, for solving existing skill
In art, the quick method for changing humans and animals muscle fiber types has that adverse reaction is more, range of application is narrow and is difficult to realization
Technological deficiency.
The technical scheme in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention, this area is common
The every other embodiment that technical staff is obtained under the premise of creative work is not made, belongs to the model of present invention protection
Enclose.
In order to the present invention is described in more detail, with reference to embodiment is to a kind of composition of present invention offer and its is improving
Application in animal muscle fiber types, is specifically described.
Embodiment 1
The present embodiment is the specific embodiment for preparing above-mentioned composition product.
Product 1 is the mixture of butanedioic acid 40g, succinic acid derivative 30g and butanedioic acid metabolite 30g.In product 1,
Succinic acid derivative is sodium succinate, and butanedioic acid metabolite is fumaric acid.
Product 2 is the mixture of butanedioic acid 40g, succinic acid derivative 30g and butanedioic acid metabolite 30g.In product 2,
Succinic acid derivative is amber acid glyceride, and butanedioic acid metabolite is hydroxy succinic acid.
Product 3 is the mixture of butanedioic acid 40g, succinic acid derivative 30g and butanedioic acid metabolite 30g.In product 3,
Succinic acid derivative is ethyl succinate, and butanedioic acid metabolite is methylsuccinic acid.
Product 4 is the mixture of butanedioic acid 50g and succinic acid derivative 50g.In product 4, succinic acid derivative is amber
Sour sodium.
Product 5 is the mixture of butanedioic acid 50g and butanedioic acid metabolite 50g.In product 5, butanedioic acid metabolite is
Fumaric acid.
Product 6 is the mixture of succinic acid derivative 50g and butanedioic acid metabolite 50g.In product 6, butanedioic acid derives
Thing is sodium succinate, and butanedioic acid metabolite is fumaric acid.
Product 7 is butanedioic acid.
Embodiment 2
The present embodiment is to determine the specific embodiment that product 7 obtained in embodiment 1 improves exercise tolerance.
3 weeks male C57BL6 mouse 33 are selected in experiment, are randomly divided into 3 groups, every group 11.Wherein, first group is blank
Control group, feeds basal diet;Second group of group feeds the basal diet containing 0.5% product 7, and the 3rd group of feeding contains 1% product
Free choice feeding and drinking-water during the basal diet of product 7, three groups of mouse tests.
Raise to the 7th week, by mouse as being run on mouse treadmill, jogged with the speed of 10m/min, determine small
The endurance of mouse, the mouse for feeding this combination product is can be seen that from Fig. 1 results, and the duration of jogging is significantly higher than control group.
Mouse is placed in mouse grip meter, holds the tail of mouse, mouse in order to prevent non-original idea motion backward and instinct
Catch front grip bar, until experimenter's pulling force exceed mouse maximum grip, when mouse unclamp grab bar when, record instrument
The maximum of device.Can be drawn by Fig. 2, feed the mouse of this combination product, maximum grip is significantly higher than control mice.
Meanwhile, detect mice skeletal muscle fiber types with enzyme activity and myoglobulin heavy chain.Result finds that mouse takes product
Product 7 can significantly improve muscle slow switch fibers ratio, reduce fast muscle fiber ratio.
Can show that product 7 obtained in the present embodiment 1 can effectively improve exercise tolerance and muscular force from embodiment 2
Amount.
Embodiment 3
The present embodiment is to determine the specific embodiment that product 7 obtained in embodiment 1 improves content of hemoglobin.
3 weeks male C57BL6 mouse 33 are selected in experiment, are randomly divided into 3 groups, every group 11.Wherein, first group is blank
Control group, feeds basal diet;Second group of group feeds the basal diet containing 0.5% product 7, and the 3rd group of feeding contains 1% product
Free choice feeding and drinking-water during the basal diet of product 7, three groups of mouse tests.
Feed by the 10th week, Mouse whole blood is collected in eyeball of mouse blood sampling, and mouse hemoglobin is detected with whole blood analyser
Content.Experimental results refer to Fig. 3, from the figure 3, it may be seen that feeding this combination product can significantly improve content of hemoglobin.
Can show that product 7 obtained in the present embodiment 1 can effectively improve content of hemoglobin from embodiment 3.
Embodiment 4
The present embodiment is to determine the specific embodiment that product 7 obtained in embodiment 1 improves myoglobin content.
3 weeks male C57BL6 mouse 33 are selected in experiment, are randomly divided into 3 groups, every group 11.Wherein, first group is blank
Control group, feeds basal diet;Second group of group feeds the basal diet containing 0.5% product 7, and the 3rd group of feeding contains 1% product
Free choice feeding and drinking-water during the basal diet of product 7, three groups of mouse tests.
Feed by the 10th week, take the content that Gastrocnemius Muscle of Cancer detects mouse myoglobins.Experimental results refer to figure
4, Fig. 4 results illustrate that feeding this combination product can significantly improve the content of myoglobins in muscle.
Can show that product 7 obtained in the present embodiment 1 can effectively improve myoglobin content from embodiment 4.
Embodiment 5
The present embodiment is the specific embodiment for determining the reduction of product 7 blood-sugar content obtained in embodiment 1.
3 weeks male C57BL6 mouse 33 are selected in experiment, are randomly divided into 3 groups, every group 11.Wherein, first group is blank
Control group, feeds basal diet;Second group of group feeds the basal diet containing 0.5% product 7, and the 3rd group of feeding contains 1% product
Free choice feeding and drinking-water during the basal diet of product 7, three groups of mouse tests.
Experimental period is 10 weeks, the morning 8 on every Mondays during experiment:30 determine mouse blood sugar.Experimental results refer to figure
5, drawn by Fig. 5 results, feed the mouse blood sugar substantially less than control group mice blood sugar of this combination product.
Can show that product 7 obtained in the present embodiment 1 can effectively reduce blood-sugar content from embodiment 5.
Embodiment 6
The present embodiment is the specific embodiment for determining the reduction blood fat content of product 7 obtained in embodiment 1.
3 weeks male C57BL6 mouse 33 are selected in experiment, are randomly divided into 3 groups, every group 11.Wherein, first group is blank
Control group, feeds basal diet;Second group of group feeds the basal diet containing 0.5% product 7, and the 3rd group of feeding contains 1% product
Free choice feeding and drinking-water during the basal diet of product 7, three groups of mouse tests.
Feed by the 10th week, mice serum is collected in eyeball of mouse blood sampling, and kit detects containing for serum free fatty acid
Amount, experimental results refer to Fig. 6.Result of study finds that feeding this combination product can significantly reduce serum free fatty acid
Content.
Can be drawn from embodiment 6, product 7 obtained in the present embodiment 1, can effective reduction blood fat content.
Embodiment 7
The present embodiment is to determine the specific embodiment that product 7 obtained in embodiment 1 promotes wound healing.
3 weeks male C57BL6 mouse 16 are selected in experiment, and random machine is divided into 2 groups, every group 8.First group is blank
Group, carries out leg incised wound operation, feeds basal diet, drinking pure water;Second group is treatment group, carries out leg incised wound operation,
Feeding basal diet, addition contains 1% product 7 in drinking water.Free choice feeding and drinking-water during two groups of mouse tests.
Mouse leg wound healing situation is then observed, experimental results refer to Fig. 7.As shown in Figure 7, control group is small
Mouse recovers 18 days or so the time of normal need, and adds the treatment group containing 1% product 7, the wound healing of mouse leg in drinking water
Normally 12 days or so time is only needed to recovery.
Can show that product 7 obtained in the present embodiment 1 can effectively facilitate wound healing from embodiment 7.
Embodiment 8
The present embodiment is the specific embodiment for determining the quality of the improvement of product 7 meat obtained in embodiment 1.
Improve the effect of meat quality to study this combination, select 70 kilograms or so the miscellaneous fattening pigs 180 of ternary, according to
Body weight is close, the ratio of male and female half and half is randomly divided into 3 groups, and 6 repeating groups of each group, each repeating groups include 10
Pig.Wherein, control group fed basal diet, test group 1 adds 2kg/ tons of product 7 in basal diet, and test group 2 is in basic day
2kg/ tons of product 7 is added in grain.The miscellaneous fattening pig of ternary of the experiment free choice feeding and drinking-water during testing.
Raising terminates for 45 days, and raising selects the pig 18 (each repeating groups one) in average weight or so after terminating,
Slaughter determining its Meat Quality Traits.According to detection, the improvement result of gained meat quality refers to table 1.
The meat of table 1 improves situation
The result of table 1 shows that this combination is added in daily ration can significantly improve yellowish pink, while improving 24 hours whole pH value, reduces
Drip loss.Product 7 obtained in the present embodiment 1, can effectively improve the quality of meat.
1~product of product 6 repeats the experiment of 2~embodiment of embodiment 8, obtains the experimental result similar with product 7, herein
Repeat no more.
Can be drawn from embodiment 2~8, a kind of composition that the present invention is provided, exercise tolerance can be effectively improved, blood is improved
Lactoferrin content, raising myoglobin content, reduction blood-sugar content, reduction blood fat content, promotion Wound healing and improvement meat
The quality of product, further, effectively can quickly change humans and animals muscle fiber types, have a good application prospect.
The present invention provide technical scheme, with it is following a little:
1st, using simplicity, without injection;
2nd, medicine and time cost are low, and aerobic exercise is done without extra hunting time and place;
3rd, action effect is fast, can reach the technique effect for changing humans and animals muscle fiber types within usual 3~4 weeks.
In sum, the invention provides a kind of composition, the composition includes:Butanedioic acid, succinic acid derivative and
One or more in butanedioic acid metabolite.Improving exercise tolerance, improving blood red present invention also offers above-mentioned composition
Protein content, raising myoglobin content, reduction blood-sugar content, reduction blood fat content, promotion wound healing and improvement meat
Quality in application.Through experimental tests can be obtained, the composition that the present invention is provided, and can be effectively improved exercise tolerance, be improved blood red
Protein content, the quality for improving myoglobin content, reducing blood-sugar content, reduction blood fat content and improvement meat, can be effective
Ground is quick to change humans and animals muscle fiber types.Meanwhile, in the composition that the present invention is provided, butanedioic acid and its derivative are in vivo
The succinate of row belongs to the conventional intermediate product of internal metabolism, and the generation of adverse reaction will not be typically caused to human body.Solution
Determined in the prior art, the quick method for changing humans and animals muscle fiber types have that adverse reaction is more, range of application is narrow and
It is difficult to the technological deficiency realized.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (11)
1. a kind of composition, it is characterised in that the composition includes:Butanedioic acid, succinic acid derivative and amber acid metabolic are produced
One or more in thing.
2. composition according to claim 1, it is characterised in that in terms of mass parts, the composition includes:Butanedioic acid 0
0~100 part of~100 parts, 0~100 part of succinic acid derivative and butanedioic acid metabolite.
3. composition according to claim 1, it is characterised in that the succinic acid derivative is selected from:Succinate, amber
One or more in sour methyl esters, ethyl succinate, amber propyl propionate, and amber acid glyceride.
4. composition according to claim 1, it is characterised in that the butanedioic acid metabolite is selected from:Fumaric acid, hydroxyl
One or more in base butanedioic acid and methylsuccinic acid.
5. application of a kind of composition including described in Claims 1-4 any one in exercise tolerance is improved.
6. application of a kind of composition including described in Claims 1-4 any one in content of hemoglobin is improved.
7. application of a kind of composition including described in Claims 1-4 any one in myoglobin content is improved.
8. application of a kind of composition including described in Claims 1-4 any one in blood-sugar content is reduced.
9. application of a kind of composition including described in Claims 1-4 any one in reduction blood fat content.
10. application of a kind of composition including described in Claims 1-4 any one in wound healing is promoted.
A kind of application of 11. compositions including described in Claims 1-4 any one in the quality of improvement meat.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611131091.8A CN106727476A (en) | 2016-12-09 | 2016-12-09 | A kind of composition and its application in animal muscle fiber types is improved |
CN201710774928.9A CN107456449A (en) | 2016-12-09 | 2017-08-31 | A kind of composition and its application in muscular endurance is increased |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611131091.8A CN106727476A (en) | 2016-12-09 | 2016-12-09 | A kind of composition and its application in animal muscle fiber types is improved |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106727476A true CN106727476A (en) | 2017-05-31 |
Family
ID=58879569
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611131091.8A Pending CN106727476A (en) | 2016-12-09 | 2016-12-09 | A kind of composition and its application in animal muscle fiber types is improved |
CN201710774928.9A Pending CN107456449A (en) | 2016-12-09 | 2017-08-31 | A kind of composition and its application in muscular endurance is increased |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710774928.9A Pending CN107456449A (en) | 2016-12-09 | 2017-08-31 | A kind of composition and its application in muscular endurance is increased |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN106727476A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116369533A (en) * | 2023-03-29 | 2023-07-04 | 中国人民解放军东部战区总医院 | Physical enhancement supplement composition and product containing same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1452482A (en) * | 2000-04-10 | 2003-10-29 | 维尔吉列斯基·巴维尔·瓦西列维奇 | Synergistic compositions contg. choline base and cuccinic acid for insulin resistance and diabetes |
CN1318370A (en) * | 2000-04-18 | 2001-10-24 | 萧湘 | Application of fumaric acid in preparing medicine |
-
2016
- 2016-12-09 CN CN201611131091.8A patent/CN106727476A/en active Pending
-
2017
- 2017-08-31 CN CN201710774928.9A patent/CN107456449A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116369533A (en) * | 2023-03-29 | 2023-07-04 | 中国人民解放军东部战区总医院 | Physical enhancement supplement composition and product containing same |
Also Published As
Publication number | Publication date |
---|---|
CN107456449A (en) | 2017-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chatzifotis et al. | Effect of dietary lipid levels on growth, feed utilization, body composition and serum metabolites of meagre (Argyrosomus regius) juveniles | |
Lazzarini et al. | Nutritional performance of cattle grazing during rainy season with nitrogen and starch supplementation | |
Fadiyimu et al. | Digestibility, nitrogen balance and haematological profile of West African dwarf sheep fed dietary levels of Moringa oleifera as supplement to Panicum maximum | |
CN101366451B (en) | Feedstuff additive for improving oil and fat assimilation utilization ratio and preparation method thereof | |
Wang et al. | Effect of almond hulls as an alternative ingredient on broiler performance, nutrient digestibility, and cecal microbiota diversity | |
Sarvari et al. | Effects of dietary zinc oxide and a blend of organic acids on broiler live performance, carcass traits, and serum parameters | |
Alparslan et al. | The effects of diet containing fish oil on some blood parameters and the performance values of broilers and cost efficiency | |
Saeid et al. | Effect of adding garlic powder (Allium sativum) and black seed (Nigella sativa) in feed on broiler growth performance and intestinal wall structure | |
CN101595946A (en) | A kind of meat modifier and preparation method thereof and application | |
CN101801370B (en) | Composition comprising sesamin component and arachidonic acid component | |
Biswas et al. | Combined effect of photoperiod and self-feeder on the growth performance of striped knifejaw, Oplegnathus fasciatus | |
CN106727476A (en) | A kind of composition and its application in animal muscle fiber types is improved | |
Milton | Digestive physiology in primates | |
RU2634049C1 (en) | Method of correction of energy-metabolic processes in rapid horses in the period of training and rosygrysh of traditional prizes | |
Garcia et al. | Effects of supplementation with Saccharomyces cerevisiae and aerobic training on physical performance of Mangalarga Marchador mares | |
Maheshwari et al. | Physiological response of Bligon buck to transportation: Relation to level of thyroid hormone | |
RU2777285C1 (en) | Method for feeding broiler chickens with a feed additive | |
Lassoued et al. | Reproductive and productivity traits of goats grazing Acacia cyanophylla Lindl. with and without daily PEG supplementation | |
CN107027976A (en) | Poultry Water Soluble Compound nutritious supplementary pharmaceutical and preparation method thereof | |
Sokerya et al. | Effects of ensiled cassava (Manihot esculenta) foliage compared to a soybean meal supplement on gastrointestinal nematode infections in goats | |
RU2067860C1 (en) | Method of treatment of piglet with postnatal hypertrophy | |
RU2540354C1 (en) | Method of feeding fur-bearing animals | |
Hofmeyr | The use of hormones in meat production: Hot potato or key to food security? | |
Brandao | Using Dual-Flow Continuous Culture System to Estimate Ruminal Fermentation Responses to Dietary Manipulations | |
CHETAN | 12. A REVIEW ON ROLE OF SUPPLEMENTATION OF ORGANIC ACIDS ON BROILER'S PERFORMANCE by SINGH CHETAN 1 AND PANDYA SUCHIT S. 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |